Taxus Breezes Through Panel On Cypher Drag, Possibly Raising Data Bar
This article was originally published in The Gray Sheet
Executive Summary
The FDA Circulatory System Devices Panel endorsed Boston Scientific's proposed ARRIVE 2,000-patient, five-year Taxus postmarket study with no additional conditions beyond proposals made by the company
You may also be interested in...
Taxus “Peri-approval” Trial Offers Postmarket Study Model – Zuckerman
FDA is encouraging PMA sponsors to file a continued-access protocol for a long-term trial that will meet postmarket study requirements following a device's approval
Taxus “Peri-approval” Trial Offers Postmarket Study Model – Zuckerman
FDA is encouraging PMA sponsors to file a continued-access protocol for a long-term trial that will meet postmarket study requirements following a device's approval
Cordis Parries Taxus Approval Thrust With REALITY Procedure Success Data
Post-market surveillance of Boston Scientific's Taxus paclitaxel-eluting stent will cover over 3,500 patients and include five-year follow-up on more than 1,500 patients treated in pre-market trials